Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.20 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-03-24
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $800.00K, a 60.00% increase year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-12-31 was $300.00K.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-09-30 was $500.00K.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $1.30M, a 62.50% increase from fiscal 2018.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $800.00K, a 74.19% decline from fiscal 2017.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $3.10M, a 72.22% increase from fiscal 2016.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $1.80M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2020-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.20M 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $400.00K 10-Q · filed 2020-08-12 | ||||
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $800.00K derived: sum of 2 quarters · filed 2021-03-24 | $1.30M 10-K · filed 2021-03-24 | ||
| 2019-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.00M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $800.00K 10-K · filed 2020-03-19 | $1.90M 10-K · filed 2019-02-21 | |||
| 2017-12-31 | $3.10M 10-K · filed 2019-02-21 | ||||
| 2016-12-31 | $1.80M 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |